CVS Q3 Preview: Accelerating Growth, Near 3% Yield, Meaningful Upside Long-Term

CVS Health has executed a robust turnaround, prompting an upgrade from hold to buy with a $115 price target. Accelerating earnings, raised guidance, improved margins, and reduced leverage underpin a strengthened long-term investment case for CVS. Dividend safety is enhanced by strong free cash flow and a low payout ratio, supporting income investors amid potential volatility.

Seeking Alpha • Oct 28, 2026

Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research • Oct 28, 2026

Did CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Oct 27, 2026

CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

CVS Health (CVS) closed the most recent trading day at $91.13, moving 1.51% from the previous trading session.

Zacks Investment Research • Oct 27, 2026

Should You Buy CVS Health Stock While It's Under $100?

After a couple of challenging years, CVS Health has been generating some improved numbers in 2026. The company is expecting a significant improvement on the bottom line this year.

The Motley Fool • Oct 26, 2026

CVS Health Q3 Earnings Preview: How to Approach the Stock?

CVS' third-quarter 2026 results face mixed segment trends, with Aetna's margin recovery and digital investments offering support amid persistent 340B pressures and membership declines.

Zacks Investment Research • Oct 26, 2026

Aetna Provider Survey Shows Payer-Provider Trust Remains Strong; Providers say Reducing Fraud can Significantly Lower Health Care Costs

6.0 trust score consistent with significant improvement reported in Q2 Fewer providers single out prior authorization as the main driver of administrative burden, and they reveal their next recommended focus area Respondents believe that addressing fraud, waste and abuse can reduce the cost of care HARTFORD, Conn., Oct. 26, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced findings from the Q3 Aetna Provider Survey.

PRNewsWire • Oct 26, 2026

CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS). On August 2, 2023, the Company announced its financial results for the quarter ended June 30, 2023, disclosing that it was revising its diluted earnings-per-share ("EPS") guidance range to $6.53 to $6.75 fr.

Business Wire • Oct 26, 2026

CVS Pharmacy expands fall assortment of collectibles, nostalgic favorites and seasonal exclusives

New and expanded offerings across toys, collectibles, beauty, snacks and seasonal categories give shoppers more opportunities to discover unexpected finds WOONSOCKET, R.I., Oct. 23, 2026 /PRNewswire/ -- CVS Pharmacy®, the retail division of CVS Health® (NYSE: CVS), today announced an expanded assortment of collectibles, nostalgic favorites, limited-edition products and seasonal finds for fall, introducing new brands, exclusive products and trending products across toys, beauty, snacks and seasonal categories.

PRNewsWire • Oct 23, 2026

Is Trending Stock CVS Health Corporation (CVS) a Buy Now?

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Oct 23, 2026